Community Connection: Ovarian Cancer Canada is looking for volunteers! Could you help?

OVdialogue – consider joining our team in the role of Community Champion. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis (mfallis@ovariancanada.org).
The new OVdialogue experience is only days away! Here’s what the updated platform will offer you as a valued member of our peer-to-peer community:
• A personalized experience, just for you: your member homepage displays the content you engage with most, including a resource library where you can engage in discussions directly related to the content.
• Have conversations in real time: You can respond to notifications and personal messages from people in your community directly from your email inbox; plus it’s easier than ever to return to the platform.
• Stay up to date on the latest events: upcoming activities will be listed in an events calendar right here in the platform
During this time of transition, private messaging within the platform will be unavailable beginning January 22, and posting will be unavailable beginning January 27.
We look forward to seeing you in the refreshed platform!

Research opportunity: Eligible for PARP inhibitor maintenance therapy but not taking it?

mfallis
mfallis admin
in News & Events

The below information is to inform you of a research study about ovarian cancer maintenance therapy in Canada. This study is conducted by Broadstreet HEOR on behalf of GlaxoSmithKline (also called “GSK”). GSK is a company that discovers and makes vaccines, medicines, and other healthcare products. Ovarian Cancer Canada is committed to driving research forward, and therefore shares relevant research opportunities with those affected by ovarian cancer, where appropriate.


If you have been diagnosed with ovarian cancer, you may qualify to take part in a 60-min virtual interview about your experiences. Broadstreet HEOR (a Canadian health research company) wants to speak with adults with ovarian cancer who have received chemotherapy treatment in Canada and were eligible for PARP inhibitor maintenance therapy afterward but decided against taking it. Instead, you are being closely monitored by your doctor and not on any active cancer drugs or treatments.

Anyone who qualifies and participates will receive $80. All information and responses will remain confidential.

To check if you’re eligible, email Jessica Dunne at ovariancancerstudy@broadstreetheor.com.



Comments

Categories